← Back to all signals
RESEARCH PAPER ANALYSIS

Bioactive compounds and exercise in aging and neurodegeneration: mechanistic insights from the gut-brain-metabolic axis.

This review synthesizes preclinical and limited clinical evidence that dietary bioactive compounds and physical exercise converge on a 'neuro‑nutritional‑metabolic axis'—encompassing gut‑brain signaling, metabolic regulation, mitochondrial function, and anti‑inflammatory/neurotrophic pathways—to…

PMID42027568
JournalFrontiers in nutrition
Publication Date2026-01-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This review synthesizes preclinical and limited clinical evidence that dietary bioactive compounds and physical exercise converge on a 'neuro‑nutritional‑metabolic axis'—encompassing gut‑brain signaling, metabolic regulation, mitochondrial function, and anti‑inflammatory/neurotrophic pathways—to…

WHY IT MATTERS

Research significance

The paper highlights modifiable, mechanistically plausible targets (dietary bioactives, exercise, gut‑brain and metabolic pathways, mitochondria, inflammation) that could inform multimodal neuroprotective interventions, biomarker selection, and translational studies for Parkinson's despite limited…

ABSTRACT

Source abstract

Aging and neurodegenerative disorders are associated with impaired hippocampal plasticity, yet existing literature largely examines exercise, nutrition, or metabolic regulation in isolation. This review synthesizes emerging evidence supporting an integrative neuro-nutritional-metabolic framework in which bioactive compounds and physical exercise converge to modulate hippocampal neurogenesis, synaptic plasticity, and cognitive resilience. Recent investigative efforts elucidate the neuro-nutritional-metabolic axis as a pivotal interface that integrates bioactive compounds derived from diet, systemic metabolic processes, and neuronal functionality. In this review, the term 'neuro-nutritional-metabolic axis' refers to an integrative framework describing the bidirectional interactions among dietary bioactive compounds, systemic metabolic regulation, and central nervous system plasticity. This concept extends established models such as the microbiota-gut-brain axis and muscle-brain communication by emphasizing their convergence on metabolic and neurotrophic signaling pathways relevant to hippocampal function. Simultaneously, physical exercise is acknowledged as a significant modulator of neurotrophic signaling pathways, mitochondrial performance, and neuroinflammatory responses. This review synthesizes mechanistic evidence derived predominantly from preclinical studies alongside emerging but comparatively limited clinical findings to evaluate how bioactive compounds and physical exercise interact to influence hippocampal plasticity and cognitive function. We examine the convergence of these interventions on essential molecular pathways, as well as antioxidant and anti-inflammatory cascades, to facilitate neuronal survival, synaptic reorganization, and cognitive resilience. Moreover, we investigate their potential to mitigate metabolic dysfunction, oxidative stress, and chronic inflammation, which are pivotal factors contributing to cognitive deterioration in the context of aging and neurodegenerative conditions such as Alzheimer's and Parkinson's disease. Comprehending these synergistic interactions lays the groundwork for formulating tailored, multimodal interventions that specifically address the neuro-nutritional-metabolic axis to enhance memory retention, optimize learning processes, and support cognitive resilience and may contribute to the modulation of risk factors associated with neurodegenerative conditions.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic